Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ohr Pharmceutial (OHRP)

Ohr Pharmceutial (OHRP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,249
  • Shares Outstanding, K 2,829
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,240 K
  • 60-Month Beta 0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.69
Trade OHRP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.72
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/13/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +77.89%
on 07/03/19
5.75 -6.26%
on 07/12/19
+2.00 (+59.00%)
since 06/12/19
3-Month
2.15 +150.70%
on 04/22/19
5.75 -6.26%
on 07/12/19
+3.12 (+137.44%)
since 04/12/19
52-Week
1.60 +236.88%
on 01/02/19
6.28 -14.17%
on 10/09/18
+1.19 (+28.33%)
since 07/12/18

Most Recent Stories

More News
Glaucoma Drugs Market Size | Global Industry Analysis and Opportunity Assessment 2021-2027

The latest research report on delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
US Glaucoma Drugs Market Size 2021 By Trends Evaluation, Business Opportunities, Consumption, Growth Rate, Top Manufacturer, New Project Investment, Regional Analysis and Forecast to 2027

AI Market Report is working on a new report title Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027? Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration...

AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Educative: Can Businesses recover from COVID-19 impact in Glaucoma Drugs Market

A recent report on provides a detailed analysis on the industry size, revenue forecasts and geographical landscape pertaining to this business space. Additionally, the report highlights primary obstacles...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Glaucoma Drugs Market Opportunities, Demands and Growth Revenue by 2025 | Brandessence Market Research Report

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
CANF : 1.8400 (+2.22%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
Europe Glaucoma Drugs Market Share, Size, Future Demand, Application, Top Leading Player, Upcoming Trends, Region By Forecast To 2025

A research report on features a succinct analysis on the latest market trends. The report also includes detailed abstracts about statistics, revenue forecasts and market valuation, which additionally...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
CANF : 1.8400 (+2.22%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019

Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital

OHRP : 5.39 (+30.19%)
NBSE : 8.82 (+1.61%)
Glaucoma Drugs Market 2019 Top Key Players are Aerie Pharmaceuticals, Allergan plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co. Inc., Pfizer Inc., Merck & Co., and Forecast to 2025

: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?.Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration and Diabetic Retinopathy in the aging population...

AERI : 18.75 (-2.60%)
AGN : 193.02 (+0.02%)
ITEK : 3.04 (-5.00%)
MRK : 73.13 (+1.33%)
NMUS : 0.6500 (-9.52%)
NVS : 84.01 (+0.61%)
OCAT : 8.47 (+0.12%)
OCUL : 18.51 (+6.81%)
OHRP : 5.39 (+30.19%)
PRGO : 41.04 (+1.16%)
PFE : 34.39 (+0.56%)
SNPHF : 13.6000 (-3.55%)
SCMP : 18.05 (+0.28%)
TEVA : 10.52 (-0.57%)
VRX.TO : 30.80 (-3.33%)
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical

Company expects to initiate trading on NASDAQ Under Ticker Symbol "NBSE" effective July 15, 2019

NBSE : 8.82 (+1.61%)
OHRP : 5.39 (+30.19%)
Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.

Ohr Pharmaceutical, Inc. ("Ohr") (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc. ("NeuBase") were approved by Ohr's stockholders at a special...

OHRP : 5.39 (+30.19%)
Ohr Pharmaceutical Urges Stockholders to Vote "FOR" Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019

-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal

OHRP : 5.39 (+30.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 6.81
1st Resistance Point 6.10
Last Price 5.39
1st Support Level 4.33
2nd Support Level 3.27
3rd Support Level N/A

See More

52-Week High 6.28
Last Price 5.39
Fibonacci 61.8% 4.49
Fibonacci 50% 3.94
Fibonacci 38.2% 3.39
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar